



Singapore eDevelopment Limited

(Company Registration Number 200916763W)
7 Temasek Boulevard, #29-01B
Suntec Tower One, Singapore 038987

Singapore eDevelopment Limited (Stock Code 40V)'s biomedical subsidiary confirms the LB2 drug efficacy against Ebola

Highlights:

- LB2 is a new anti-viral drug under development
- Ebola is probably the most virulent infection known
- Testing done in one of the most sophisticated testing centre in the world
- Tested against T-705 (Favipiravir) – currently the most effective anti-viral drug for the treatment of Ebola
- LB2 drug was effective at concentrations multi-fold lower as compared to T-705 (Favipiravir)
- LB2 drug demonstrates similar broad efficacy against SARS, MERS, H5N1 Avian Bird Flu, MRSA, and Cholera

SINGAPORE, 28 February 2018 – Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) (“**SeD**”), through its subsidiary, Global BioLife Inc. (“**Global BioLife**”) has completed the Zaire Ebola virus (“**Ebola**”) research portion for the study of a new anti-viral drug called LB2, which is part of the universal therapeutic drug platform, Linebacker.

The first documented outbreak of Ebola was documented in 1976, with more recent notable outbreaks occurring between 2014 – 2016. With fatality rates of up to 90%, Ebola is a severe viral disease transmitted from wild animals to human beings through physical contact, then spreads through human to human contact. There are very few treatment options for Ebola, making infection prevention and infection control practices the number one defence against the viral disease.

Global BioLife built upon the existing research of Mr. Daryl Thompson, founder of advance research company, GRDG Sciences, LLC., and Global BioLife’s Director of Scientific Initiatives. Leveraging on Mr. Daryl Thompson’s expertise in organic and carbohydrate chemistry and the use of pandemic technology in the research and development of the LB2 drug in combatting Ebola, the LB2 drug displayed efficacy at a much lower dose than the only widely used therapeutic agent for Ebola infection, T-705 (Favipiravir). Since 2014, T-705 (Favipiravir) has been used as an experimental anti-viral drug for the treatment of Ebola. Testing of T-705 (Favipiravir) has shown the anti-viral drug to be effective in decreasing the mortality rate in patients when administered approximately 48 to 72 hours after the Ebola infection. Testing for Global BioLife’s new anti-viral drug, LB2, was conducted in the biosafety level 4 (“**BSL-4**”) laboratory, the highest classification for biosafety laboratories, in Galveston, Texas. BSL-4 laboratories

28 February 2018

Page 2 of 3

are used to study life-threatening diseases, employing state-of-the-art systems to protect researchers, staff and the general public from contamination.

Dr. Roscoe Moore, former Assistant Surgeon General of the United States and who serves as the Scientific Advisor to the Linebacker Project, commented, “The results validate our core belief that the Linebacker platform can be a major entry as an effective small molecule anti-infective – effective and at the same time, with a good safety profile.”

In addition to Ebola, the LB2 drug demonstrates similar broad efficacy against SARS, MERS, H5N1 Avian Bird Flu, MRSA, and Cholera. Based on this, Global BioLife is moving forward with their research efforts and expect to see results of the LB2 drug against ZIKA, Malaria, and the influenza pandemic.

“Based on the Ebola data alone, as one of the currently known most potent new anti-viral drug candidate and yet with the lowest toxicity, we have high hopes that the LB2 drug has the potential to make real impact in improving people’s health globally,” said Dr. Tang Peihong, Global BioLife’s Director and Chief Executive Officer. Dr. Tang Peihong has a Ph.D. in Chemical Engineering from Columbia University, USA and worked for Merck & Co., Inc., a Fortune 500 company, in 1995 as a Senior Engineer focusing on pharmaceutical process engineering and technical services.

Mr. Chan Heng Fai, Executive Chairman of SeD said, “Global BioLife is at the cutting edge of research into real solutions for global health problems.”

The rest of the Linebacker platform is currently wrapping up pre-clinical testing against an array of diseases. Global BioLife expects to have the remainder of the validating laboratory data on the universal therapeutic drug platform, including Alzheimer’s and Parkinson’s disease, within the next four (4) months.

Shareholders and potential investors of SeD are advised to exercise caution when dealing or trading in the securities of SeD. In particular, shareholders and potential investors of SeD should note that there is no certainty or assurance that the transactions mentioned in this announcement will materialise. Shareholders and potential investors of SeD are advised to read this Media Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

End of Release

28 February 2018

Page 3 of 3

About Singapore eDevelopment Limited

Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities.

For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.

About Global BioLife Inc.

Global BioLife Inc. (“**GBLI**”) is a 70%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. The remaining shareholding of Global BioLife Inc. is held by Global Research and Discovery Group Scientific LLC (“**GRDGS**”) at 20% and Australian Exchange-listed Holista CollTech Limited (“**Holista**”) at 10%.

With an aging population and a growing focus in healthcare issues, biomedical science has become increasingly vital. GBLI strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDGS and Holista, GBLI pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition and treatment of neurological, oncology and immuno-related diseases. GBLI is also collaborating with its partners to develop second generation mosquito defense technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika and Dengue.

For more information, please visit: <http://www.globalbiolife.com>.

About GRDG Sciences, LLC.

GRDG Sciences, LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson.

For more information, please visit: <http://www.globalrdg.com>.

This Media Release has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, Hong Leong Finance Limited (the “Sponsor”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the “SGX-ST”). The Sponsor has not independently verified the contents of this Media Release.

This Media Release has not been examined or approved by SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this Media Release, including the correctness of any of the statements or opinions made or reports contained in this Media Release.

The contact person for the Sponsor is Mr Tang Yeng Yuen, Vice President, Head of Corporate Finance, Hong Leong Finance Limited, at 16 Raffles Quay, #02-05 Hong Leong Building, Singapore 048581, telephone: +65 6415 9886.